TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Files An 8-K Financial Statements and Exhibits

Tracon Pharmaceuticals, Inc. ExhibitEX-99.1 2 tcon-ex991_6.htm EX-99.1 tcon-ex991_6.htm Exhibit 99.1 Santen and TRACON Announce Initiation of a Phase 2a Study of DE-122 for the Treatment of Wet Age-Related Macular Degeneration Osaka,…To view the full exhibit click here
About TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company’s lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Recent Trading Information
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) closed its last trading session up +0.05 at 2.25 with 32,455 shares trading hands.